Strengthening R&D Capabilities and Enhancing Customer Responsiveness
First written in FY2016. 26 of 35 entries say "Restated". Latest entry: FY2026.
21 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The Group has 351 R&D employees, accounting for approximately one-fifth of its total workforce. R&D expenses across the Group for the consolidated fiscal year totaled ¥5,275 million, including ¥1,355 million in R&D expenses related to new businesses that were not allocated to reportable segments as company-wide expenses.」
The company disclosed 351 R&D employees and R&D expenses of ¥5,275 million, and updated its R&D framework, including the recognition of R&D expenses for new businesses as company-wide expenses. - 2026-05-13AdvancedEarnings
「R&D expenses 5,275 5,158」
R&D expenses increased from ¥5.158 billion in the previous fiscal year to ¥5.275 billion in the current fiscal year. - FY2026-H1RestatedAnnual report
「The amount spent on R&D activities across the Group during the interim consolidated fiscal period was ¥2,643 million. There were no material changes in the status of R&D activities during the interim consolidated fiscal period.」
The company stated that there were no material changes in R&D activities and disclosed interim-period R&D expenses of ¥2,643 million. - FY2025AdvancedAnnual report
「The Group has 353 R&D employees, accounting for approximately one-fifth of its total workforce. R&D expenses across the Group for the consolidated fiscal year totaled ¥5,158 million, including ¥1,112 million in R&D expenses related to new businesses that were not allocated to reportable segments as company-wide expenses.」
The company disclosed 353 R&D employees and R&D expenses of ¥5,158 million, and provided details on the development, adoption and start of sales of products including peptide fertilizer, odor sensors, silk elastin, lubricant additives for EVs and an extracellular vesicle purification kit. - FY2025-H1RestatedAnnual report
「The amount spent on R&D activities across the Group during the interim consolidated fiscal period was ¥2,545 million. There were no material changes in the status of R&D activities during the interim consolidated fiscal period.」
The company disclosed R&D expenses of ¥2,545 million and continued to state that there were no material changes in the status of R&D activities. - FY2024AdvancedAnnual report
「The Group has 370 R&D employees, accounting for approximately one-fifth of its total workforce. R&D expenses for the consolidated fiscal year totaled ¥5,222 million, including ¥1,245 million in R&D expenses related to new businesses that were not allocated to reportable segments as company-wide expenses, and the main R&D results of each segment are as follows.」
The company disclosed 370 R&D employees and R&D expenses of ¥5,222 million, and provided details of results including peptide fertilizer, silk elastin, an extracellular vesicle purification kit and electronic materials. - FY2024-Q3RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative third quarter of the consolidated fiscal year was ¥3,884 million. There were no material changes in the status of R&D activities during the cumulative third quarter of the consolidated fiscal year.」
The company disclosed cumulative third-quarter R&D expenses of ¥3,884 million and continued to state that there were no material changes in the status of R&D activities. - FY2024-Q2RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative second quarter of the consolidated fiscal year was ¥2,610 million. There were no material changes in the status of R&D activities during the cumulative second quarter of the consolidated fiscal year.」
The company disclosed R&D expenses of ¥2,610 million and continued to state that there were no material changes in the status of R&D activities. - FY2024-Q1RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative first quarter of the consolidated fiscal year was ¥1,409 million. There were no material changes in the status of R&D activities during the cumulative first quarter of the consolidated fiscal year.」
The company disclosed cumulative first-quarter R&D expenses of ¥1,409 million and continued to state that there were no material changes in the status of R&D activities. - FY2023AdvancedAnnual report
「The Group has 397 R&D employees, accounting for approximately one-fifth of its total workforce. R&D expenses for the consolidated fiscal year totaled ¥5,691 million across the Group, and the main R&D results of each segment are as follows.」
The company disclosed 397 R&D employees and R&D expenses of ¥5,691 million, and described R&D results including peptide-based agriculture, all-resin batteries, chemical recycling and environmentally friendly materials. - FY2023-Q3RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the third quarter of the current cumulative consolidated period was ¥4,293 million. There were no material changes in the status of R&D activities during the third quarter of the current cumulative consolidated period.」
The company stated that there were no material changes in R&D activities and disclosed third-quarter cumulative R&D expenses of ¥4,293 million. - FY2023-Q2RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the second quarter of the current cumulative consolidated period was ¥2,876 million. There were no material changes in the status of R&D activities during the second quarter of the current cumulative consolidated period.」
The company disclosed second-quarter cumulative R&D expenses of ¥2,876 million and stated that there were no material changes in R&D activities. - FY2023-Q1RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the first quarter of the current cumulative consolidated period was ¥1,402 million. There were no material changes in the status of R&D activities during the first quarter of the current cumulative consolidated period.」
The company disclosed first-quarter cumulative R&D expenses of ¥1,402 million and continues to state that there have been no material changes in R&D activities. - FY2022-Q3RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the third quarter of the current cumulative consolidated period was ¥4,190 million. There were no material changes in the status of R&D activities during the third quarter of the current cumulative consolidated period.」
The company disclosed R&D expenses of ¥4,190 million and continues to state that there have been no material changes in the status of R&D activities. - FY2022-Q2RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the second quarter of the current cumulative consolidated period was ¥2,785 million. There were no material changes in the status of R&D activities during the second quarter of the current cumulative consolidated period.」
The company continues to state that there have been no material changes in R&D activities and disclosed second-quarter cumulative R&D expenses of ¥2,785 million. - FY2022-Q1RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the first quarter of the current cumulative consolidated period was ¥1,402 million. There were no material changes in the status of R&D activities during the first quarter of the current cumulative consolidated period.」
The company disclosed R&D expenses of ¥1,402 million and continues to state that there have been no material changes in the status of R&D activities. - FY2021AdvancedAnnual report
「The group has 432 R&D personnel, representing approximately one-fifth of its total workforce. Group-wide R&D expenses for the current consolidated fiscal year were ¥5,384 million, and the main R&D results by segment are as follows.」
The company disclosed 432 R&D personnel and R&D expenses of ¥5,384 million, and described results including successful demonstration testing of all-resin batteries and the adoption and launch of new products. - FY2021-Q3RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the third quarter of the current cumulative consolidated period was ¥3,928 million. There were no material changes in the status of R&D activities during the third quarter of the current cumulative consolidated period.」
The company stated that there were no material changes in R&D activities and disclosed third-quarter cumulative R&D expenses of ¥3,928 million. - FY2021-Q2RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the second quarter of the current cumulative consolidated period was ¥2,588 million. There were no material changes in the status of R&D activities during the second quarter of the current cumulative consolidated period.」
The company stated that there were no material changes in R&D activities and disclosed second-quarter cumulative R&D expenses of ¥2,588 million. - FY2021-Q1RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the first quarter of the current cumulative consolidated period was ¥1,280 million. There were no material changes in the status of R&D activities during the first quarter of the current cumulative consolidated period.」
The company disclosed R&D expenses of ¥1,280 million and stated that there were no material changes in the status of R&D activities. - FY2020-Q3RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the third quarter of the current cumulative consolidated period was ¥4,281 million. There were no material changes in the status of R&D activities during the third quarter of the current cumulative consolidated period.」
The company disclosed R&D expenses of ¥4,281 million and stated that there were no material changes in the status of R&D activities. - FY2020-Q2RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the second quarter of the current cumulative consolidated period was ¥2,837 million. There were no material changes in the status of R&D activities during the second quarter of the current cumulative consolidated period.」
The company disclosed first-half cumulative R&D expenses of ¥2,837 million and stated that there were no material changes in the status of R&D activities. - FY2020-Q1RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the first quarter of the current cumulative consolidated period was ¥1,430 million. There were no material changes in the status of R&D activities during the first quarter of the current cumulative consolidated period.」
The company disclosed first-quarter cumulative R&D expenses of ¥1,430 million and stated that there were no material changes in the status of R&D activities. - FY2019AdvancedAnnual report
「The group has 425 R&D personnel, representing approximately one-fifth of its total workforce. Group-wide R&D expenses for the current consolidated fiscal year were ¥5,569 million, and the main R&D results by segment are as follows.」
The company disclosed 425 R&D personnel and R&D expenses of ¥5,569 million, and described results including adoption by overseas adhesive tape manufacturers and automakers and the development of new products. - FY2019-Q3RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the third quarter of the current cumulative consolidated period was ¥4,150 million. There were no material changes in the status of R&D activities during the third quarter of the current cumulative consolidated period.」
The company disclosed third-quarter cumulative R&D expenses of ¥4,150 million and stated that there were no material changes in the status of R&D activities. - FY2019-Q2RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the second quarter of the current cumulative consolidated period was ¥2,756 million. There were no material changes in the status of R&D activities during the second quarter of the current cumulative consolidated period.」
The company disclosed first-half cumulative R&D expenses of ¥2,756 million and stated that there were no material changes in the status of R&D activities. - FY2019-Q1RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the first quarter of the current cumulative consolidated period was ¥1,358 million. There were no material changes in the status of R&D activities during the first quarter of the current cumulative consolidated period.」
The company disclosed R&D expenses of ¥1,358 million and stated that there were no material changes in the status of R&D activities. - FY2018R&D structure and results updatedAnnual report
「The group has 416 R&D personnel, representing approximately one-fifth of its total workforce. Group-wide R&D expenses for the current consolidated fiscal year were ¥5,365 million, and the main R&D results by segment are as follows.」
The company updated its figures to 416 R&D personnel, approximately one-fifth of its total workforce, and R&D expenses of ¥5,365 million, and provided specific results including medical materials, lubricant additives, and battery materials. - FY2018-Q3RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the third quarter of the current cumulative consolidated period was ¥4,019 million. There were no material changes in the status of R&D activities during the third quarter of the current cumulative consolidated period.」
The company stated that there were no material changes in R&D activities and disclosed 9-month cumulative R&D expenses of ¥4,019 million. - FY2018-Q2RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the second quarter of the current cumulative consolidated period was ¥2,704 million. There were no material changes in the status of R&D activities during the second quarter of the current cumulative consolidated period.」
The company disclosed first-half cumulative R&D expenses of ¥2,704 million and stated that there were no material changes in the status of R&D activities. - FY2018-Q1RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the first quarter of the current cumulative consolidated period was ¥1,354 million. There were no material changes in the status of R&D activities during the first quarter of the current cumulative consolidated period.」
The company disclosed first-quarter cumulative R&D expenses of ¥1,354 million and stated that there were no material changes in the status of R&D activities. - FY2017-Q3RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the third quarter of the current cumulative consolidated period was ¥4,028 million. There were no material changes in the status of R&D activities during the third quarter of the current cumulative consolidated period.」
The company stated that there were no material changes in R&D activities and disclosed 9-month cumulative R&D expenses of ¥4,028 million. - FY2017-Q2RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the second quarter of the current cumulative consolidated period was ¥2,723 million. There were no material changes in the status of R&D activities during the second quarter of the current cumulative consolidated period.」
The company stated that there were no material changes in R&D activities and disclosed first-half cumulative R&D expenses of ¥2,723 million. - FY2017-Q1RestatedAnnual report
「The amount spent on R&D activities by the group as a whole during the first quarter of the current cumulative consolidated period was ¥1,359 million. There were no material changes in the status of R&D activities during the first quarter of the current cumulative consolidated period.」
The company reported quarterly R&D expenses of ¥1,359 million and stated that there were no material changes in R&D activities. - FY2016First statedAnnual report
「With contributing to society through performance chemicals (functional chemicals) as its basic strategy, our group (the company and its consolidated subsidiaries) is actively engaged in research and development, including deepening its core technologies, developing new products, and strengthening its ability to respond to customers. R&D is currently being conducted by the Research Division, Development Research Division, Research Operations Division, the Research Department of the Lubricant Additives Business Division, the R&D departments of each subsidiary, and the research departments of consolidated subsidiaries SDP Global Co., Ltd., Sun Nopco Co., Ltd., and San Apro Co., Ltd. The group has 425 R&D personnel, representing approximately one-quarter of its total workforce.」
The company presents an R&D structure of 425 people, approximately one-quarter of its total workforce, focused on deepening core technologies, developing new products, and responding to customers.